Director's Dealing

27 May 2014 Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Director's Dealing

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that David Evans, a director, has today purchased 210,000 ordinary shares of 0.1 pence each in the Company at a price of 20.5 pence per share.

David Evans now holds 289,033 ordinary shares of 0.1 pence each, representing 1.03 per cent. of the Company's issued share capital.